ArticleACS omega2026
Reverse Phase High Performance Liquid Chromatography Method for the Estimation of Mangiferin in Nano Formulations: Development and Optimization by Analytical Quality-by-Design.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel reverse-phase high-performance liquid chromatography (RP-HPLC) method was developed and optimized for the estimation of Mangiferin (MGF) by employing a Quality by Design (QbD) approach. Preliminary method screening was done by the Taguchi OA, followed by using a Box-Behnken Design (BBD), enabling systematic evaluation of critical factors with a reduced number of experimental runs. The model efficiently established significant correlations between selected variables and analytical responses, thereby enhancing the method's robustness and reliability. Chromatographic separation was achieved on a Hyperclone C18 column (4.6 × 250 mm, 5 μm) using an isocratic mobile phase consisting of phosphate buffer (pH 3.2) and acetonitrile (30%) + methanol (70%) in a 78:22% v/v ratio, at a flow rate of 1.0 mL/min. Detection was performed using a photodiode array detector at 258 nm. The method was validated in accordance with ICH Q2-(R2) guidelines. Validation parameters, including system suitability, linearity, accuracy, precision, robustness, sensitivity, and solution stability, were found within acceptable limits. The proposed method was successfully applied for the analysis of the stability study of MGF and to analyze the release kinetics of MGF SLNs, formulated via high-pressure homogenization and the sonication technique. The results confirm the applicability of the developed RP-HPLC method for routine quality control of combination nanocarrier systems.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.